Medicare drug plan seen as only short-term windfall for drugmakers

The new Medicare prescription drug plan would appear to be a windfall for the pharmaceutical industry, increasing earnings by 2% to 3% over the next two years; but in the long term the government and health plans are likely to negotiate lower prices, analysts and industry executives say.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA